SteinstraesserA, SchmidtR, BergmannK, DahmenR, BeckerRH. Investigational new insulin glargine 300 U/mL has the same metabolism as glargine 100 U/mL. Diabetes Obes Metab, 2014; 16: 873–76.
2.
DanneT, BeckerRH, PingL, PhilotheouA. Insulin glargine metabolite 21(A)-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatr Diabetes, 2015; 16: 299–304.
3.
GersteinHC, BoschJ, DagenaisGR, DiazR, JungH, MaggioniAP, PougeJ, ProbstfieldJ, RamachandranA, RiddleMC, RydénLE, YusufS. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012; 367: 319–28.
4.
RitzelR, RousselR, BolliGB, VinetL, Brulle-WohlhueterC, GlezerS, Yki-JärvinenH. Patient-level meta-analysis of the EDITION 1,2 and 3 studies: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab, 2015; 17: 859–67.
5.
BiesterT, BlaesigS, RemusK, AschemeierB, KordonouriO, GranhallC, SøndergaardF, KristensenNR, HaahrH, DanneT. Insulin degludec's pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes, 2014; 15: 27–33.
6.
NiskanenL, LeiterLA, FranekE, WengJ, DamciT, Muñoz-TorresM, DonnetJ-P, EndahlL, SkjøthTV, VaagA. Comparison of a soluble co-formulation of insulin degludec/aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol, 2012; 167: 287–94.
7.
RosenstockJ, BergenstalRM, BlevinsTC, MorrowLA, PrinceMJ, QuY, SinhaVP, HoweyDC, JacoberSJ. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes. Diabetes Care, 2013; 36: 522–28.
8.
BergenstalRM, RosenstockJ, ArakakiRF, PrinceMJ, QuY, SinhaVP, HoweyDC, JacoberSJ. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care, 2012; 35: 2140–47.
9.
PolimeniG, TrifiroG, IngrasciottaY, CaputiAP. The advent of biosimilars for the treatment of diabetes: current status and future directions. Acta Diabetol, 2015; 52: 423–31.
10.
FranzeS, CilurzoF, MinghettiP. Insulin biosimilars: the impact on rapid-acting analog-based therapy. BioDrugs, 2015; 29: 113–21.
11.
HeinemannL, HomePD, HompeschM. Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes Obes Metab, 2015; 17: 911–8.
12.
DeVriesJH, GoughSC, KiljanskiJ, HeinemannL. Biosimilar insulins: a European perspective. Diabetes Obes Metab, 2015; 17: 445–51.
13.
HeinemannL, KhatamiH, McKinnonR, HomeP: An overview of current regulatory requirements for approval of biosimilar insulins. Diabetes Technol Ther, 2015; 17: 510–26.
14.
HeinemannL, HompeschM. Biosimilar insulins: how similar is similar?. J Diabetes Sci Technol, 2011; 5: 741–54.
15.
Lavalle-GonzalezFJ, KhatamiH. The biosimilar insulin landscape: current developments. Postgrad Med, 2014; 126: 81–92.
16.
Garcia-NaresH, Leyva-CarmonaMI, Perez-XochipaN, ChiqueteE. Hypersensitivity reaction to a biosimilar insulin glargine. J Diabetes, 2015; 7: 155–57.
17.
A Two Part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants with Type 1 Diabetes Mellitus (Part II) (MK-2640-001) [article online], May15, 2015. Available at https://clinicaltrials.gov/ct2/show/NCT02269735.
